The Competition Commission clears phase II review of the proposed acquisition by novartis ag of the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline plc* ISLAMABAD, MONDAY, 09 FEBRUARY 2015: The Competition Commission of Pakistan ("Commission") has concluded the Phase II review of the pre-merger application dated 29 August, 2014 by clearing the proposed acquisition by which Novartis AG (“Novartis”), intends to acquire the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline
The Pakistan Competition Commission clears an acquisition, following an in-depth investigation, in the pharmaceutical sector (Novartis / GSK)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.